Pemvidutide vs Tirzepatide

Pemvidutide is an experimental GLP-1 and glucagon dual agonist still in development, with no FDA-approved uses yet. Tirzepatide, sold as Mounjaro or Zepbound, is an approved GIP and GLP-1 dual agonist used to treat type 2 diabetes, obesity, and obstructive sleep apnea. Unlike pemvidutide, tirzepatide is already on the market and comes in injectable form.

AI summary of the sources below.